US Parkinson's disease market to see considerable drop in market share, from 32% in 2009 to 25% in 2019

In 2009, the Parkinson's disease market generated $2.2 billion across the seven major markets. As the market approaches maturity, Datamonitor forecasts the growth to slow from a compound annual growth rate of 7.9% (2005-09) to 2.2% (2009-19), as pipeline entries partially offset the generic erosion of key brand sales.

The major Parkinson's disease growth driver over the 2005-09 period was the dopamine agonist class, which accounted for nearly half the therapy sector market sales, supported by the continued uptake of the newer catechol-O-methyltransferase (COMT) inhibitor and monoamine oxidase inhibitor (MAOI) classes. Parkinson's disease market growth is set to slump, as an unimpressive late-stage pipeline will fail to offset generic incursion.

The US market will experience a considerable drop in market share, from 32% in 2009 to 25% in 2019, as generics take hold. New reformulations and the novel adenosine A2a receptor antagonist drugs do not offer the benefits or differentiation required to usurp traditional therapies.